These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 25018782)

  • 1. Serum HE4, CA125, YKL-40, bcl-2, cathepsin-L and prediction optimal debulking surgery, response to chemotherapy in ovarian cancer.
    Chudecka-Głaz AM; Cymbaluk-Płoska AA; Menkiszak JL; Sompolska-Rzechuła AM; Tołoczko-Grabarek AI; Rzepka-Górska IA
    J Ovarian Res; 2014; 7():62. PubMed ID: 25018782
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum HE4 superior to CA125 in predicting poorer surgical outcome of epithelial ovarian cancer.
    Shen Y; Li L
    Tumour Biol; 2016 Nov; 37(11):14765-14772. PubMed ID: 27629144
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preoperative serum levels of HE4 and CA125 predict primary optimal cytoreduction in advanced epithelial ovarian cancer: a preliminary model study.
    Feng LY; Liao SB; Li L
    J Ovarian Res; 2020 Feb; 13(1):17. PubMed ID: 32050995
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Role of HE4, a Novel Biomarker, in Predicting Optimal Cytoreduction After Neoadjuvant Chemotherapy in Advanced Ovarian Cancer.
    Plotti F; Scaletta G; Capriglione S; Montera R; Luvero D; Lopez S; Gatti A; De Cicco Nardone C; Terranova C; Angioli R
    Int J Gynecol Cancer; 2017 May; 27(4):696-702. PubMed ID: 28406844
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Significance of HE4 estimation in comparison with CA125 in diagnosis of ovarian cancer and assessment of treatment response.
    Hamed EO; Ahmed H; Sedeek OB; Mohammed AM; Abd-Alla AA; Abdel Ghaffar HM
    Diagn Pathol; 2013 Jan; 8():11. PubMed ID: 23343214
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Performance of preoperative plasma tumor markers HE4 and CA125 in predicting ovarian cancer mortality in women with epithelial ovarian cancer.
    Furrer D; Grégoire J; Turcotte S; Plante M; Bachvarov D; Trudel D; Têtu B; Douville P; Bairati I
    PLoS One; 2019; 14(6):e0218621. PubMed ID: 31220149
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic accuracy of CA125 and HE4 in ovarian carcinoma patients and the effect of confounders on their serum levels.
    Ahmed AA; Abdou AM
    Curr Probl Cancer; 2019 Oct; 43(5):450-460. PubMed ID: 30670303
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum HE4 and CA125 as predictors of response and outcome during neoadjuvant chemotherapy of advanced high-grade serous ovarian cancer.
    Vallius T; Hynninen J; Auranen A; Carpén O; Matomäki J; Oksa S; Virtanen J; Grénman S
    Tumour Biol; 2014 Dec; 35(12):12389-95. PubMed ID: 25190018
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The value of 18F-FDG PET/CT imaging combined with detection of CA125 and HE4 in the diagnosis of recurrence and metastasis of ovarian cancer.
    Sun J; Cui XW; Li YS; Wang SY; Yin Q; Wang XN; Gu L
    Eur Rev Med Pharmacol Sci; 2020 Jul; 24(13):7276-7283. PubMed ID: 32706065
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Can the preoperative HE4 level predict optimal cytoreduction in patients with advanced ovarian carcinoma?
    Angioli R; Plotti F; Capriglione S; Aloisi A; Montera R; Luvero D; Miranda A; Cafà EV; Damiani P; Benedetti-Panici P
    Gynecol Oncol; 2013 Mar; 128(3):579-83. PubMed ID: 23220563
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HE4 combined with CA125: favorable screening tool for ovarian cancer.
    Ghasemi N; Ghobadzadeh S; Zahraei M; Mohammadpour H; Bahrami S; Ganje MB; Rajabi S
    Med Oncol; 2014 Jan; 31(1):808. PubMed ID: 24323399
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HE4 and CA125 as preoperative risk stratifiers for lymph node metastasis in endometrioid carcinoma of the endometrium: A retrospective study in a cohort with histological proof of lymph node status.
    O'Toole SA; Huang Y; Norris L; Power Foley M; Shireen R; McDonald S; Kamran W; Ibrahim N; Ward M; Thompson C; Murphy C; D'Arcy T; Farah N; Heron E; O'Leary JJ; Abu Saadeh F; Gleeson N
    Gynecol Oncol; 2021 Feb; 160(2):514-519. PubMed ID: 33213897
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Postoperative human epididymis protein 4 predicts primary therapy outcome in advanced epithelial ovarian cancer.
    Vallius T; Hynninen J; Auranen A; Matomäki J; Oksa S; Roering P; Grènman S
    Tumour Biol; 2017 Feb; 39(2):1010428317691189. PubMed ID: 28218038
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The differential diagnostic value and clinical significance of serum HE4 in ovarian disease with elevated CA125.
    Li W; Wang D
    Arch Gynecol Obstet; 2020 May; 301(5):1219-1225. PubMed ID: 32266526
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Can HE4 predict platinum response during first-line chemotherapy in ovarian cancer?
    Angioli R; Capriglione S; Aloisi A; Guzzo F; Luvero D; Miranda A; Damiani P; Montera R; Terranova C; Plotti F
    Tumour Biol; 2014 Jul; 35(7):7009-15. PubMed ID: 24748235
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel index for preoperative, non-invasive prediction of macro-radical primary surgery in patients with stage IIIC-IV ovarian cancer-a part of the Danish prospective pelvic mass study.
    Karlsen MA; Fagö-Olsen C; Høgdall E; Schnack TH; Christensen IJ; Nedergaard L; Lundvall L; Lydolph MC; Engelholm SA; Høgdall C
    Tumour Biol; 2016 Sep; 37(9):12619-12626. PubMed ID: 27440204
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A multiplex biomarker assay improves the diagnostic performance of HE4 and CA125 in ovarian tumor patients.
    Leandersson P; Åkesson A; Hedenfalk I; Malander S; Borgfeldt C
    PLoS One; 2020; 15(10):e0240418. PubMed ID: 33075095
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proofs for implementation of higher HE4 and ROMA index cut-off values in ovarian cancer preoperative stratification.
    Špacir Prskalo Z; Bulić P; Langer S; Gaće M; Puljiz M; Danolić D; Alvir I; Mamić I; Šušnjar L; Mayer L
    J Obstet Gynaecol; 2019 Feb; 39(2):195-201. PubMed ID: 30207507
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of ovarian cancer remission markers HE4, MMP7 and Mesothelin by comparison to the established marker CA125.
    Schummer M; Drescher C; Forrest R; Gough S; Thorpe J; Hellström I; Hellström KE; Urban N
    Gynecol Oncol; 2012 Apr; 125(1):65-9. PubMed ID: 22155417
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Does HE4 have a role as biomarker in the recurrence of ovarian cancer?
    Plotti F; Capriglione S; Terranova C; Montera R; Aloisi A; Damiani P; Muzii L; Scaletta G; Benedetti-Panici P; Angioli R
    Tumour Biol; 2012 Dec; 33(6):2117-23. PubMed ID: 22875782
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.